articleThe LancetJan 21, 2024Closed access

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

JSJeffrey S. WeberMSMatteo S. CarlinoAKAdnan KhattakTMTarek MeniawyGAGeorge Ansstas

NYU Langone Health · Blacktown & Mount Druitt Hospital · +29 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

705
total citations
FWCI
176.73
Percentile
100%
References
33
Citations per year

Authors

34

Topics & keywords

Topics
Keywords
  • Pembrolizumab
  • Medicine
  • Internal medicine
  • Hazard ratio
  • Melanoma
  • Clinical endpoint
  • Oncology
  • Ipilimumab
No related works found for this paper.

Funding